If you are a dispenser of drugs in the U.S. that purchased one or more Drugs at Issue from January 1, 2010, through March 5, 2024, you may be entitled to benefits from a Settlement.

The purpose of this website is to provide information concerning Settlements with In re Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 16-md-2724 (E.D. Penn.).

If you have any questions after reading this website, you should contact lead counsel or the Settlement Administrator. Please do not call or write to the court.

Please read this website carefully and in its entirety. You may be a member of the Classes described below and your rights may be affected by this pending class action lawsuit. This website advises you of your options regarding the class action and the Settlements.


Important Information about your Rights:

You are a “Settlement Class Member” if you satisfy the following: All dispensers of drugs (including hospitals and independent pharmacies) in the United States and its territories that purchased one or more of the Drugs at Issue directly from distributor AmerisourceBergen Corp., Cardinal, Red Oak, Harvard, H.D. Smith, McKesson, Morris & Dickson or WBAD or their subsidiaries; and all dispensers of drugs (including hospitals and independent pharmacies) in the State Damages Jurisdictions that purchased one or more of the Drugs at Issue from any source other than the manufacturer Defendants from January 1, 2010 through March 5, 2024.

A $1 million Settlement has been reached in a class action antitrust lawsuit filed on behalf of the Indirect Reseller Plaintiffs and Defendant Breckenridge Pharmaceutical, Inc. (“Breckenridge” or “Settling Defendant”). The Settlement only applies to the Settling Defendant Breckenridge and does not dismiss the allegations against other Defendants in the lawsuit entitled In re Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 16-md-2724 (E.D. Penn.).

To receive settlement benefits in the Breckenridge Settlement, you must submit a timely and valid Claim Form online or by mail. Claim Forms may be submitted until 90 days following the Court’s final approval of the Settlement Agreement. The court will hold a hearing on November 17, 2026 to determine whether to grant final approval of the Settlement.

Please visit the Frequently Asked Questions section on this website for more information regarding this Settlement.


Current Status

Recently, notice was provided regarding a settlement with Defendant Breckenridge Pharmaceutical, Inc, a new settlement within the same lawsuit. You must submit separate Claim Forms for the Breckenridge Defendant and Apotex Defendant.


Breckenridge Settlement Important Dates
  • August 6, 2026
    Deadline to Exclude Yourself from the Settlement
  • August 6, 2026
    Deadline to Object to the Settlement
  • November 17, 2026
    Final Approval Hearing